Kenneth J. Hillan - Jun 5, 2023 Form 4 Insider Report for 23andMe Holding Co. (ME)

Role
Chief Therapeutics Officer
Signature
/s/ Kenneth Hillan, by Kathy Hibbs, attorney-in-fact
Stock symbol
ME
Transactions as of
Jun 5, 2023
Transactions value $
-$31,922
Form type
4
Date filed
6/7/2023, 04:20 PM
Previous filing
Jun 5, 2023
Next filing
Dec 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ME Class A Common Stock Award $0 +44.4K +23.01% $0.00 237K Jun 5, 2023 Direct F1
transaction ME Class A Common Stock Tax liability -$31.9K -15.3K -6.47% $2.08 222K Jun 5, 2023 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units (the "RSUs") granted under the 23andMe Amended and Restated Annual Incentive Plan and the 23andMe Holding Co. 2021 Incentive Equity Plan (together, the "Plans") as payment of the reporting person's annual incentive bonus for the fiscal year ended March 31, 2023. The RSUs are fully vested at the time of grant and are subject to the terms and conditions of the Plans, the applicable award agreement, and applicable tax withholding obligations. Each RSU represents the contingent right to receive one share of Class A common stock of 23andMe Holding Co.
F2 The closing price on June 5, 2023, the fair market value used for the transaction date.